Target Q2 FY26 GAAP EPS more than doubles to $4.11; net sales rise 5.3% to $26.5 billion
Reuters2026/08/19 10:31- Target posts Q2 GAAP diluted EPS of USD 4.11, doubled from a year ago, including USD 1.65 per share tariff-refund benefits.
- Net earnings doubled to USD 1.88 billion; operating income climbed 94.4% to USD 2.56 billion, boosted by USD 994 million pretax refunds.
- Net sales rose 5.3% to USD 26.54 billion; comparable sales increased 3.8%, driven by 3.6% higher comparable traffic.
- Operating margin widened 4.4 percentage points to 9.6%; gross margin rate expanded 4.7 percentage points to 33.7%.
- Outlook lifted: full-year net sales growth seen around 5%; GAAP diluted EPS guidance set at USD 9.90-USD 10.90.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million
TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Crypto prices
More
